Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
1,211,675
-
Shares change
-
+137,745
-
Total reported value, excl. options
-
$3,948,923
-
Value change
-
+$448,806
-
Number of buys
-
9
-
Number of sells
-
-3
-
Price
-
$3.26
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q3 2022
20 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q3 2022.
Gain Therapeutics, Inc. - COM (GANX) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,211,675 shares
.
Largest 10 shareholders include GREENLIGHT CAPITAL INC (546,560 shares), Telemetry Investments, L.L.C. (150,000 shares), CM Management, LLC (125,000 shares), GEODE CAPITAL MANAGEMENT, LLC (87,967 shares), PRELUDE CAPITAL MANAGEMENT, LLC (58,100 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (40,000 shares), ROYAL BANK OF CANADA (39,000 shares), RENAISSANCE TECHNOLOGIES LLC (33,400 shares), Wealth Alliance Advisory Group, LLC (25,000 shares), and RAYMOND JAMES & ASSOCIATES (24,000 shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.